Refuge Biotechnologies Inc., a company developing chimeric antigen receptor (CAR) T-cell therapies designed to enable multitargeted cancer treatment, has raised a $25 million series B round. The new funds will support advancement of multiple CRISPR-leveraging candidates, including the company's lead, the preclinical CAR RB-1916 for diffuse large B-cell lymphoma.